Listed

Cabaletta Bio, Inc.: Form 10-Q for the period ended Mar 31, 2025

Filed with the SEC on May 15, 2025 and accepted by EDGAR at May 15, 2025, 07:10 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2025-01-01 to 2025-03-31$29.0mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2025-01-01 to 2025-03-31−$37.1mus-gaap:OperatingIncomeLoss
Interest expense3 months2025-01-01 to 2025-03-31$294.0kus-gaap:InterestExpense
Income tax3 months2025-01-01 to 2025-03-31$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2025-01-01 to 2025-03-31−$35.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2025-01-01 to 2025-03-31−$0.71us-gaap:EarningsPerShareDiluted
Basic EPS3 months2025-01-01 to 2025-03-31−$0.71us-gaap:EarningsPerShareBasic
Operating cash flow3 months2025-01-01 to 2025-03-31−$30.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2025-01-01 to 2025-03-31$785.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2025-03-31$131.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-03-31$134.6mus-gaap:AssetsCurrent
Total assetsAt period end2025-03-31$165.1mus-gaap:Assets
Current liabilitiesAt period end2025-03-31$34.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2025-03-31$43.6mus-gaap:Liabilities
Shareholders' equityAt period end2025-03-31$121.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950170-25-071971. Last ingested by Listed: Oct 30, 2026, 11:27 ET. Listed shows no prices and gives no investment advice.